– USA, CA – ADARx Pharmaceuticals, Inc., a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced the appointment of Dr. Laura Shawver (Ph.D.) as Chair of its Board of Directors.
About Dr. Laura Shawver
Dr. Laura Shawver is a strategic leader with a wealth of leadership experience in the biopharma industry. She is chair of the board of directors of Adcendo ApS as well as a member of the boards of directors of ARS Pharmaceuticals (Nasdaq: SPRY) and Dovetail Therapeutics.
Dr. Laura Shawver served as President and CEO of Capstan Therapeutics. Her prior leadership roles include CEO of Silverback Therapeutics and President and CEO of Synthorx.
Dr. Laura Shawver holds a Ph.D. in Pharmacology and a B.S. in Microbiology, both from the University of Iowa.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. We have developed technology to control the expression of specific disease drivers with highly selective RNA-targeted therapies with the goal of delivering life-changing treatments for patients with urgent unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable, and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system, and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology, and oncology.
For more information: https://www.adarx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.